Literature DB >> 20044988

Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites.

Andreas Leffler1, Jennifer Reckzeh, Carla Nau.   

Abstract

Voltage-gated Na(+) channels (Na(v)) regulate the excitability of sensory neurons and are potential targets for novel analgesics. The secreolytic ambroxol reduces pain-related behavior in rodents and alleviates pain in humans. With properties resembling those of local anesthetics, ambroxol has been reported to block Na(+) currents in sensory neurons with a preference for tetrodotoxin-resistant (TTXr) Na(+) currents encoded by Na(v)1.8. However, the molecular determinants for ambroxol-induced block of Na(+) channels and a preferential block of Na(v)1.8 opposed to tetrodotoxin-sensitive (TTXs) Na(v) alpha-subunits have not been studied in detail. By means of whole-cell voltage clamp recordings, we studied the effects of ambroxol and local anesthetics on the recombinant TTXr subunit Na(v)1.8, on TTXs Na(v) alpha-subunits and on mutants of Na(v)1.4 that are insensitive to local anesthetics. Tonic and use-dependent block by ambroxol was strongly alleviated in local anesthetic-insensitive Na(v)1.4 mutants. Use-dependent block, but not tonic block was significantly stronger on Na(v)1.8 than on TTXs channels. The TTXs subunit Na(v)1.3 displayed the least degree of use-dependent block by ambroxol. The local anesthetics mepivacaine and S(-)-bupivacaine also blocked Na(v)1.8 and TTXs channels differentially. While mepivacaine displayed a preferential use-dependent block of Na(v)1.8, S(-)-bupivacaine displayed a preference for TTXs Na(+) channels. Our data show that ambroxol acts as a typical local anesthetic on Na(+) channels interacting with specific residues in the S6 segments. This property probably meditates the analgesic effect of ambroxol. Ambroxol preferentially blocks Na(v)1.8, however shares this property with established local anesthetics like mepivacaine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20044988     DOI: 10.1016/j.ejphar.2009.12.027

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain.

Authors:  Aldric T Hama; Ann Woodhouse Plum; Jacqueline Sagen
Journal:  Pharmacol Biochem Behav       Date:  2010-08-21       Impact factor: 3.533

2.  [Topical ambroxol for the treatment of neuropathic pain: A first clinical observation. German version].

Authors:  K-U Kern; T Weiser
Journal:  Schmerz       Date:  2015-12       Impact factor: 1.107

3.  Inhibition of Nav1.7 channels by methyl eugenol as a mechanism underlying its antinociceptive and anesthetic actions.

Authors:  Ze-Jun Wang; Boris Tabakoff; Simon R Levinson; Thomas Heinbockel
Journal:  Acta Pharmacol Sin       Date:  2015-06-08       Impact factor: 6.150

4.  Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes.

Authors:  Jonathan W Theile; Theodore R Cummins
Journal:  Front Pharmacol       Date:  2011-10-04       Impact factor: 5.810

5.  Inhibition of inflammatory pain and cough by a novel charged sodium channel blocker.

Authors:  Ivan Tochitsky; Sooyeon Jo; Nick Andrews; Masakazu Kotoda; Benjamin Doyle; Jaehoon Shim; Sebastien Talbot; David Roberson; Jinbo Lee; Louise Haste; Stephen M Jordan; Bruce D Levy; Bruce P Bean; Clifford J Woolf
Journal:  Br J Pharmacol       Date:  2021-06-21       Impact factor: 9.473

6.  Functional up-regulation of Nav1.8 sodium channel in Aβ afferent fibers subjected to chronic peripheral inflammation.

Authors:  Mounir Belkouch; Marc-André Dansereau; Pascal Tétreault; Michael Biet; Nicolas Beaudet; Robert Dumaine; Ahmed Chraibi; Stéphane Mélik-Parsadaniantz; Philippe Sarret
Journal:  J Neuroinflammation       Date:  2014-03-07       Impact factor: 8.322

Review 7.  Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents.

Authors:  Steven C Mitini-Nkhoma; Elizabeth T Chimbayo; David T Mzinza; David V Mhango; Aaron P Chirambo; Christine Mandalasi; Agness E Lakudzala; Dumizulu L Tembo; Kondwani C Jambo; Henry C Mwandumba
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

8.  Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis.

Authors:  Jean-François Chenot; Peter Weber; Tim Friede
Journal:  BMC Fam Pract       Date:  2014-03-13       Impact factor: 2.497

9.  Characterization of Endogenous Sodium Channels in the ND7-23 Neuroblastoma Cell Line: Implications for Use as a Heterologous Ion Channel Expression System Suitable for Automated Patch Clamp Screening.

Authors:  Marc Rogers; Nace Zidar; Danijel Kikelj; Robert W Kirby
Journal:  Assay Drug Dev Technol       Date:  2016-03       Impact factor: 1.738

10.  Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation.

Authors:  K-U Kern; T Weiser
Journal:  Schmerz       Date:  2015-12       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.